Tranexamic Acid Treatment for Heavy Menstrual Bleeding

Lukes, Andrea S.; Moore, Keith A.; Muse, Ken N.; Gersten, Janet; Hecht, Bryan R.; Edlund, Måns; Richter, Holly E.; Eder, Scott Evan; Attia, George R.; Patrick, Donald L.; Rubin, Arkady; Shangold, Gary A.

doi:10.1097/aog.0b013e3181f20177

Cited by 199 publications

(127 citation statements)

References 21 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Treatment with tranexamic acid was found to reduce MBL by 34-54% compared to a placebo in different studies [21,22,23]. Our results (60.8% decrease in blood loss) were slightly more successful and were similar to the results of a phase 3, open prospective trial by Gultekin et al [24], who reported a 65.9% success rate in 2009.…”

Section: Discussionsupporting

confidence: 80%

Comparison of Therapeutic Efficacies of Norethisterone, Tranexamic Acid and Levonorgestrel-Releasing Intrauterine System for the Treatment of Heavy Menstrual Bleeding: A Randomized Controlled Study

Kiseli

Kayıkçıoğlu

Evliyaoğlu

et al. 2016

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: Our aim was to compare the therapeutic efficacies of norethisterone acid (NETA), tranexamic acid and levonorgestrel-releasing intrauterine system (LNG-IUS) in treating idiopathic heavy menstrual bleeding (HMB). Methods: Women with heavy uterine bleeding were randomized to receive NETA, tranexamic acid or LNG-IUS for 6 months. The primary outcome was a decrease in menstrual bleeding as assessed by pictorial blood loss assessment charts and hematological parameters analyzed at the 1st, 3rd and 6th months. Health-related quality of life (QOL) variables were also recorded and analyzed. Results: Twenty-eight patients were enrolled in each treatment group, but the results of only 62 were evaluated. NETA, tranexamic acid, and LNG-IUS reduced menstrual blood loss (MBL) by 53.1, 60.8, and 85.8%, respectively, at the 6th month. LNG-IUS was more effective than NETA and tranexamic acid in decreasing MBL. LNG-IUS was also more efficient than tranexamic acid in correcting anemia related to menorrhagia. Satisfaction rates were comparable among the NETA (70%), tranexamic acid (63%) and LNG-IUS (77%) groups. QOL in physical aspects increased significantly in the tranexamic acid and LNG-IUS groups. Conclusion: The positive effect of LNG-IUS on QOL parameters, as well as its high efficacy, makes it a first-line option for HMB.

show abstract

Section: Discussionsupporting

confidence: 80%

Comparison of Therapeutic Efficacies of Norethisterone, Tranexamic Acid and Levonorgestrel-Releasing Intrauterine System for the Treatment of Heavy Menstrual Bleeding: A Randomized Controlled Study

Kiseli

Kayıkçıoğlu

Evliyaoğlu

et al. 2016

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…The study evaluated an objective measurement of MBL improvement based on an alkaline hematin assay method while providing MIQ data 22 .…”

Section: Methods Overviewmentioning

confidence: 99%

“…Statistically significant treatment differences in both MBL and MIQ items were reported in the TA efficacy and safety study 22,29 . These differences suggest a strong relationship between objective and subjective assessments of menstrual blood loss.…”

Section: Further Validation Of Miq In the Randomized Clinical Trial mentioning

confidence: 97%

Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life

Bushnell¹,

Martin²,

Moore³

et al. 2010

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

show abstract

“…MBL was reduced by 39 and 40% with Lysteda 3.9 g/day compared with 2 and 8% reductions with placebo in the three-cycle study and six-cycle study, respectively. Reductions in MBL were evident during the first treatment cycle and were maintained throughout the studies (Figure 2) [13,14]. Mean MBL reduction from baseline with Lysteda treatment was both greater than 50 ml and exceeded the threshold of MBL reduction (36 ml) considered meaningful to women.…”

Section: Phase III Trialsmentioning

confidence: 99%

Tranexamic Acid: A Novel Oral Formulation for the Treatment of Heavy Menstrual Bleeding

Lukes¹,

Kouides

Moore³

2011

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Tranexamic acid, a synthetic lysine derivative, is an antifibrinolytic drug that prevents the breakdown of fibrin by competitively blocking binding sites of plasminogen. Tranexamic acid is often considered a first-line treatment for the management of heavy menstrual bleeding (HMB). A new oral formulation of tranexamic acid provides a nonhormonal HMB therapy that is safe, effective and well tolerated; is administered only during menstruation; addresses the excessive fibrinolysis implicated in many cases of HMB; and improves women's health-related quality of life by reducing limitations on physical, social and leisure activities. This article provides a summary of the clinical development, therapeutic efficacy and tolerability profile of this novel formulation of tranexamic acid for the treatment of HMB.

show abstract

Tranexamic Acid Treatment for Heavy Menstrual Bleeding

Abstract: I.

Cited by 199 publications

References 21 publications

Comparison of Therapeutic Efficacies of Norethisterone, Tranexamic Acid and Levonorgestrel-Releasing Intrauterine System for the Treatment of Heavy Menstrual Bleeding: A Randomized Controlled Study

Comparison of Therapeutic Efficacies of Norethisterone, Tranexamic Acid and Levonorgestrel-Releasing Intrauterine System for the Treatment of Heavy Menstrual Bleeding: A Randomized Controlled Study

Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life

Tranexamic Acid: A Novel Oral Formulation for the Treatment of Heavy Menstrual Bleeding

Contact Info

Product

Resources

About